Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Sanofi”

Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic TherapyWithdrawn
NCT05567406Phase 2Updated Feb 12, 2026
Sponsor: Kadmon, a Sanofi Company
Chronic Graft Versus Host Disease
Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years With Atopic DermatitisRecruiting
NCT06039241N/AUpdated Feb 12, 2026
Sponsor: Sanofi
Atopic Dermatitis
Germany
Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen to Children and Adults and as Single Booster Dose to a Subset of AdultsCompleted
NCT04127786Phase 3Updated Feb 10, 2026
Sponsor: Sanofi Pasteur, a Sanofi Company
Rabies · Healthy Volunteers
Thailand
Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).Active Not Recruiting
NCT04751877Phase 3Updated Feb 10, 2026
Sponsor: Poitiers University Hospital
Multiple Myeloma · Myeloma
France
Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma PatientsCompleted
NCT03275285Phase 3Updated Feb 9, 2026
Sponsor: Sanofi
Plasma Cell Myeloma
United States, Australia, Brazil, Canada, Czechia +11 more
Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic FibrosisCompleted
NCT03375047Phase 1, Phase 2Updated Feb 9, 2026
Sponsor: Sanofi
Cystic Fibrosis
United States
Intensified Chemotherapy in CRC After Resection of Liver MetastasesCompleted
NCT00208260Phase 2, Phase 3Updated Feb 5, 2026
Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Colorectal Cancer · Liver Metastases · Chemotherapy
France
A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe HemophiliaActive Not Recruiting
NCT05662319Phase 3Updated Feb 4, 2026
Sponsor: Sanofi
Hemophilia
United States, Canada, China, France, Germany +12 more
A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)Terminated
NCT04913220Phase 1, Phase 2Updated Feb 4, 2026
Sponsor: Sanofi
Malignant Melanoma · Squamous Cell Carcinoma of Skin
United States, Australia, Chile, France, Germany +2 more
A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry DiseaseActive Not Recruiting
NCT05206773Phase 3Updated Feb 4, 2026
Sponsor: Sanofi
Fabry Disease
United States, Argentina, Australia, Austria, Brazil +16 more
Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis SuppurativaTerminated
NCT06118099Phase 2Updated Feb 4, 2026
Sponsor: Sanofi
Hidradenitis
United States, Australia, Canada, Chile, France +6 more
Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and ToddlersTerminated
NCT06252285Phase 3Updated Feb 3, 2026
Sponsor: Sanofi Pasteur, a Sanofi Company
RSV Immunisation
United States, Argentina, Brazil, Chile, China +11 more
Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and ToddlersTerminated
NCT06397768Phase 3Updated Feb 3, 2026
Sponsor: Sanofi Pasteur, a Sanofi Company
RSV Immunization
United States, Mexico, Puerto Rico
Phase 3 Single Arm, Open Study on vYF in AdultsCompleted
NCT07222059Phase 3Updated Feb 3, 2026
Sponsor: Sanofi Pasteur, a Sanofi Company
Yellow Fever
Japan
Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in AdultsCompleted
NCT07002060Phase 3Updated Feb 2, 2026
Sponsor: Sanofi
Yellow Fever Immunization
United States
A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase AlfaActive Not Recruiting
NCT03019406Phase 2Updated Jan 30, 2026
Sponsor: Genzyme, a Sanofi Company
Glycogen Storage Disease Type II-Pompe's Disease
United States, France, Japan, Taiwan, United Kingdom
Teplizumab in Pediatric Stage 2 Type 1 DiabetesActive Not Recruiting
NCT05757713Phase 4Updated Jan 30, 2026
Sponsor: Sanofi
Diabetes Mellitus, Type 1
United States
A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis SuppurativaCompleted
NCT05849922Phase 2Updated Jan 29, 2026
Sponsor: Sanofi
Hidradenitis Suppurativa
United States, Australia, Belgium, Canada, Chile +10 more
A Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, and Safety of Venglustat in Late-onset GM2Terminated
NCT04221451Phase 3Updated Jan 28, 2026
Sponsor: Genzyme, a Sanofi Company
Tay-Sachs Disease · Sandhoff Disease
United States, Argentina, Brazil, Czechia, France +8 more
Cognitive Status, Fatigue and Inflammation in Patients With Immune Thrombocytopenia (ITP)Completed
NCT06665308N/AUpdated Jan 26, 2026
Sponsor: Sanofi
Chronic Immune Thrombocytopenia · Primary Immune Thrombocytopenia · Adult Immune Thrombocytopenia
United States, United Kingdom
Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA)Completed
NCT05687279Phase 1, Phase 2Updated Jan 26, 2026
Sponsor: Sanofi Pasteur, a Sanofi Company
Respiratory Syncytial Virus Infection
United States, Puerto Rico
The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance MelanomaCompleted
NCT00626860Phase 1, Phase 2Updated Jan 23, 2026
Sponsor: Beth Israel Deaconess Medical Center
Metastatic Melanoma
United States
A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell CarcinomaCompleted
NCT00625755Phase 1, Phase 2Updated Jan 23, 2026
Sponsor: Beth Israel Deaconess Medical Center
Renal Cell Carcinoma
United States
Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South AfricaCompleted
NCT05794230Phase 3Updated Jan 21, 2026
Sponsor: Sanofi Pasteur, a Sanofi Company
Meningococcal Immunisation · Healthy Volunteers
India, South Africa
Dengvaxia US Pregnancy RegistryRecruiting
NCT04486638N/AUpdated Jan 21, 2026
Sponsor: Sanofi Pasteur, a Sanofi Company
Dengue Virus Infection
Puerto Rico

Previous page Next page